These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 35107737)

  • 1. Risks of mucormycosis in the current Covid-19 pandemic: a clinical challenge in both immunocompromised and immunocompetent patients.
    Monika P; Chandraprabha MN
    Mol Biol Rep; 2022 Jun; 49(6):4977-4988. PubMed ID: 35107737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucormycosis, The Deadly New Worry to COVID-19 Pandemic.
    Kamrul-Hasan AB; Selim S
    Mymensingh Med J; 2021 Jul; 30(3):874-880. PubMed ID: 34226483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucormycosis, past and present: a comprehensive review.
    Gupta I; Baranwal P; Singh G; Gupta V
    Future Microbiol; 2023 Feb; 18():217-234. PubMed ID: 36970978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucormycosis and Its Upsurge During COVID-19 Epidemic: An Updated Review.
    Sharma B; Nonzom S
    Curr Microbiol; 2023 Aug; 80(10):322. PubMed ID: 37592083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucormycosis in Africa: Epidemiology, diagnosis and treatment outcomes.
    Osaigbovo II; Ekeng BE; Davies AA; Oladele RO
    Mycoses; 2023 Jul; 66(7):555-562. PubMed ID: 36856432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology, Risk Factors, Diagnosis and Treatment of Mucormycosis (Black Fungus): A Review.
    Upadhayay P; Bansal K; Goyal A
    Curr Pharm Biotechnol; 2023; 24(13):1645-1656. PubMed ID: 36941816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology, pathogenesis, clinical characteristics, and treatment of mucormycosis: a review.
    Liang M; Xu J; Luo Y; Qu J
    Ann Med; 2024 Dec; 56(1):2396570. PubMed ID: 39221718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surge of mucormycosis during the COVID-19 pandemic.
    Dam P; Cardoso MH; Mandal S; Franco OL; Sağıroğlu P; Polat OA; Kokoglu K; Mondal R; Mandal AK; Ocsoy I
    Travel Med Infect Dis; 2023; 52():102557. PubMed ID: 36805033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review on Mucormycosis: Pathogenesis, Epidemiology, Microbiology and Diagnosis.
    Sharma A; Alam MA; Dhoundiyal S; Sharma PK
    Infect Disord Drug Targets; 2024; 24(1):e220823220209. PubMed ID: 37608614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Focusing COVID-19-associated mucormycosis: a major threat to immunocompromised COVID-19.
    Sharma N; Wani SN; Behl T; Singh S; Zahoor I; Sehgal A; Bhatia S; Al-Harrasi A; Aleya L; Bungau S
    Environ Sci Pollut Res Int; 2023 Jan; 30(4):9164-9183. PubMed ID: 36454526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rampant Increase in Cases of Mucormycosis in India and Pakistan: A Serious Cause for Concern during the Ongoing COVID-19 Pandemic.
    Ghazi BK; Rackimuthu S; Wara UU; Mohan A; Khawaja UA; Ahmad S; Ahmad S; Hasan MM; Dos Santos Costa AC; Ahmad S; Essar MY
    Am J Trop Med Hyg; 2021 Aug; 105(5):1144-1147. PubMed ID: 34460426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucormycosis: An opportunistic pathogen during COVID-19.
    Mahalaxmi I; Jayaramayya K; Venkatesan D; Subramaniam MD; Renu K; Vijayakumar P; Narayanasamy A; Gopalakrishnan AV; Kumar NS; Sivaprakash P; Sambasiva Rao KRS; Vellingiri B
    Environ Res; 2021 Oct; 201():111643. PubMed ID: 34237335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review on SARS-CoV-2-associated fungal coinfections.
    Soni S; Namdeo Pudake R; Jain U; Chauhan N
    J Med Virol; 2022 Jan; 94(1):99-109. PubMed ID: 34570905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifungal Effect of Nanoparticles against COVID-19 Linked Black Fungus: A Perspective on Biomedical Applications.
    Gurunathan S; Lee AR; Kim JH
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential for rapid antigen testing for mucormycosis in the context of COVID-19.
    Thornton CR
    Expert Rev Mol Diagn; 2024 Mar; 24(3):161-167. PubMed ID: 37405409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucormycosis: update on clinical presentation, diagnosis, and treatment.
    Dailey Garnes NJM; Kontoyiannis DP
    Curr Opin Infect Dis; 2023 Dec; 36(6):427-435. PubMed ID: 37732771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mucormycosis in the time of COVID-19: risks and challenges].
    Seidel D; Sal E; Nacov JA; Cornely OA; Kurzai O
    Dtsch Med Wochenschr; 2024 May; 149(10):569-578. PubMed ID: 38657596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary mucormycosis in immunocompetent hosts diagnosed by bronchioalveolar lavage.
    Kumar S; Joshi D
    BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33846183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An extensive review on antifungal approaches in the treatment of mucormycosis.
    Chaudhari HS; Palkar OS; Abha Mishra KM; Sethi KK
    J Biochem Mol Toxicol; 2023 Sep; 37(9):e23417. PubMed ID: 37345721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histomorphological features of mucormycosis with rise and fall of COVID-19 pandemic.
    Ganesan N; Sivanandam S
    Pathol Res Pract; 2022 Aug; 236():153981. PubMed ID: 35749915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.